Efficacy of Siltuximab and 1,927 nm Fractional Laser for the Treatment of Cutaneous Manifestations in Castleman’s Disease: The Role of Dermoscopy and Reflectance Confocal Microscopy for Lesion Evaluation

IF 0.9 Q4 DERMATOLOGY

Case Reports in Dermatology Pub Date : 2024-04-08 DOI:10.1159/000536483

G. Paolino, Marco Ardigò, E. Della-Torre, Luca Moroni, N. Rizzo, Matteo Riccardo Di Nicola, V. G. Bianchi, Lorenzo Dagna, Giuseppe Alvise Ramirez, S. Mercuri

{"title":"Efficacy of Siltuximab and 1,927 nm Fractional Laser for the Treatment of Cutaneous Manifestations in Castleman’s Disease: The Role of Dermoscopy and Reflectance Confocal Microscopy for Lesion Evaluation","authors":"G. Paolino, Marco Ardigò, E. Della-Torre, Luca Moroni, N. Rizzo, Matteo Riccardo Di Nicola, V. G. Bianchi, Lorenzo Dagna, Giuseppe Alvise Ramirez, S. Mercuri","doi":"10.1159/000536483","DOIUrl":null,"url":null,"abstract":"Abstract Introduction Multicentric Castleman’s disease (MCD) with cutaneous involvement has rarely been discussed in dermatologic literature, with few reports. Cutaneous lesions in MCD may induce deep scars, causing a significant impact in the daily life of the patients. The treatment of Castleman’s disease (CD) is usually a challenge, especially in case of cutaneous involvement. Case Presentation We report the case of a 35-year-old Caucasian man with a 3-year-old history of MCD with cutaneous involvement that we treated with a combined therapy characterized by siltuximab and 1,927 nm fractional laser. The patient showed a therapeutic response, characterized by a reduction of systemic symptoms and cutaneous manifestations. Conclusion We believe that the combination of siltuximab and 1,927 nm fractional laser might have a synergistic beneficial role in patients with cutaneous iMCD and maximize esthetic outcomes. Anyway, additional evidence is needed to validate our findings.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000536483","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Introduction Multicentric Castleman’s disease (MCD) with cutaneous involvement has rarely been discussed in dermatologic literature, with few reports. Cutaneous lesions in MCD may induce deep scars, causing a significant impact in the daily life of the patients. The treatment of Castleman’s disease (CD) is usually a challenge, especially in case of cutaneous involvement. Case Presentation We report the case of a 35-year-old Caucasian man with a 3-year-old history of MCD with cutaneous involvement that we treated with a combined therapy characterized by siltuximab and 1,927 nm fractional laser. The patient showed a therapeutic response, characterized by a reduction of systemic symptoms and cutaneous manifestations. Conclusion We believe that the combination of siltuximab and 1,927 nm fractional laser might have a synergistic beneficial role in patients with cutaneous iMCD and maximize esthetic outcomes. Anyway, additional evidence is needed to validate our findings.

查看原文本刊更多论文

西妥昔单抗和1,927 nm点阵激光治疗卡斯特曼病皮肤症状的疗效：皮肤镜和反射共聚焦显微镜在病变评估中的作用

摘要引言多中心卡斯特曼病（MCD）伴有皮肤受累，在皮肤科文献中鲜有报道。多中心卡斯特曼病（MCD）的皮肤病变可诱发深度疤痕，对患者的日常生活造成严重影响。卡斯特曼病（CD）的治疗通常是一项挑战，尤其是在皮肤受累的情况下。病例介绍我们报告了一例 35 岁的白种男性病例，他有 3 年的 MCD 病史，并伴有皮肤受累，我们采用了以西妥昔单抗和 1927 纳米点阵激光为特征的联合疗法进行治疗。患者出现了治疗反应，全身症状和皮肤表现均有所减轻。结论我们认为，联合使用西妥昔单抗和 1927 纳米点阵激光可能会对皮肤 iMCD 患者起到协同增效的作用，并最大限度地提高美容效果。无论如何，还需要更多的证据来验证我们的研究结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Dermatology DERMATOLOGY-

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

9 weeks